This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Gilead (
GILD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 2.6%. By the end of trading, Gilead fell $0.86 (-1.0%) to $82.79 on average volume. Throughout the day, 12,380,860 shares of Gilead exchanged hands as compared to its average daily volume of 11,656,700 shares. The stock ranged in price between $81.80-$84.20 after having opened the day at $83.79 as compared to the previous trading day's close of $83.65. Other companies within the Drugs industry that declined today were:
Compugen (
CGEN), down 20.1%,
Medivation (
MDVN), down 14.9%,
Kindred Biosciences (
KIN), down 14.6% and
Auspex Pharmaceuticals (
ASPX), down 14.4%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $128.9 billion and is part of the health care sector. Shares are up 11.4% year to date as of the close of trading on Thursday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates
Gilead as a
buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.